ALAR Pharmaceuticals
Manufacturing · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3f Keyuan Rd. Xitun Dist. Rm. 312 No 19,...Website
www.alarpharm.comRevenue
$9.4 MillionIndustry
About ALAR Pharmaceuticals
ALAR Pharmaceuticals Org Chart
Chief Financial Officer & Business Developmen...
Is ALAR Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ALAR Pharmaceuticals
ALAR Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ALAR Pharmaceuticals launches new products
Check out if ALAR Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on ALAR Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ALAR Pharmaceuticals has new funding data
Check if ALAR Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if ALAR Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined ALAR Pharmaceuticals as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
ALAR Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ALAR Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ALAR Pharmaceuticals.
ALAR Pharmaceuticals Tech Stack
A closer look at the technologies used by ALAR Pharmaceuticals
ALAR Pharmaceuticals News & Media
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use,...Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 12, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar,...Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALAR Pharmaceuticals
Alar Pharmaceuticals Inc. specializes in the development and manufacturing of innovative pharmaceutical products, including long-acting injectable formulations. The company is focused on advancing its product pipeline and offers contract manufacturing services. Its intended clients include healthcare providers and organizations seeking cutting-edge... Read More